Reverse DCF
What growth does the market imply for TORNTPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
reasonable
18.9% implied annual FCF growth
The market's growth assumption looks achievable — it is in line with or below what this company has historically delivered.
Current Price
₹4,153
Historical Growth
18.0%
FCF Yield
1.72%
Price / FCF
58.2x
Plain English
To justify today's price of $4152.50, TORNTPHARM.NS needs to grow its free cash flow at 18.9% per year for the next 10 years. That is 0.9% faster than its historical growth rate of 18.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 9.4% | ₹1,931 | -53.5% |
| GDP rate | 10.0% | ₹2,023 | -51.3% |
| Historical | 18.0% | ₹3,883 | -6.5% |
| Implied | 18.9% | ₹4,163 | +0.2% |
At Historical Growth Rate
It would take 11 years for TORNTPHARM to organically grow into today's price assuming its historical FCF growth of 18.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.